Thank you, Stephan. I'll start with our key financial highlights on Slide 8 before getting into more details. Net sales for the first quarter were $1.3 billion, up 1% from the first quarter of 2023. This is our second consecutive quarter of year-over-year net sales growth. On a constant currency basis, net sales grew 2.4%, essentially the same year-over-year growth experienced a quarter ago. Our Q1 adjusted EBITDA was $138 million and exceeded our guidance. Our adjusted EBITDA margin was 10.9%, a 60 basis point improvement from the same period a year ago. Additionally, last year's first quarter adjusted EBITDA benefited from approximately $9 million of China grant income that did not repeat in the current year. CapEx for the first quarter was $33 million and at the low end of our guidance range. First quarter gross profit margin was 77.5% up 130 basis points compared to the first quarter of last year. Gross profit margin was favorably impacted by pricing actions we have taken provided approximately 150 basis points of benefit and which exceeded the impact of increased input costs of approximately 110 basis points. Lower inventory write-downs also contributed to the improvement in gross margin by approximately 60 basis points. Q1 diluted EPS was $0.24 and with adjusted diluted EPS of $0.49, which included a $0.03 FX headwind versus the first quarter of last year. It also included higher amortization expense as we started amortizing the implementation costs related to Herbalife One during the quarter and the nonrepeat of the China grant income I previously mentioned. For the year, we expect to recognize $30 million to $35 million of amortization expense related to Herbalife One. Our first quarter adjusted effective tax rate was 27.1%, up from 12.9% in for the first quarter 2023, which drove an approximately $0.09 unfavorable impact to adjusted diluted EPS. The lower rate in 2023 and was primarily due to the geographic mix of income and greater tax benefits from discrete events last year. We anticipate our full year 2024 adjusted effective tax rate to be approximately 30% based on our forecasted geographic mix of income and the impact of elevated interest expense following our recent debt refinancing. As Michael highlighted earlier, in March, we began implementing our new restructuring plan to get the management team closer to the market, [ delay ] of the organization, and increased management span of control. We expect the program to deliver annual savings of at least $80 million, which will be fully realized in 2025, approximately $40 million of the savings expected to be realized this year. We expect to incur total program pretax expenses of at least $60 million this year which are primarily related to severance costs and will be excluded from our adjusted results. We anticipate the majority of all actions related to this program to be completed by the end of June this year. During the first quarter, we recognized approximately $17 million of SG&A related to the program. Operating cash flows for the quarter were $14 million. We expect Q1 to be the lowest cash flow quarter of the year since it's when we pay out the Mark Hughes bonuses to our most senior distributors, which was approximately $75 million. In comparison to Q1 '23, last year's first quarter benefited from an approximately $35 million change in inventory due mostly to last year's inventory optimization program. Looking forward to the rest of 2024, we expect cash flows from operations for the remainder of the year to be approximately $250 million to $290 million. This includes the headwind of approximately $60 million to implement our restructuring program just mentioned as well as the higher interest expense associated with the new financing. In April, we completed our $1.6 billion senior secured refinancing. At the end of the first quarter, our total leverage ratio was 3.6x, which is down from the 3.9x at year-end, and we are committed to reducing our total leverage ratio to 3x by the end of 2025. And I'll speak more on this a little later. Turning to Slide 9. You can see the drivers of our year-over-year top line growth. While overall volumes were down 3.6% year-over-year, which drove an approximately $45 million headwind, it was more than offset by approximately $82 million of pricing benefits. We continue to implement pricing increases to address region or market-specific conditions, which are generally in line with local CPI increases. Unfavorable country mix was primarily due to higher sales in India, and lower sales in the U.S., partially offset by increased sales in China relative to our overall net sales portfolio. FX drove 140 basis points or about $18 million, primarily due to the continued devaluation of the Argentine peso and the Turkish lira. We continue to take regular price increases in both of these high inflationary markets. These FX headwinds were partially offset by year-over-year favorable currency movements from the Mexican peso. Moving on to regional net sales results for the first quarter on Slide 10. 4 of our 5 regions reported net sales growth in the first quarter on both a reported and local currency basis. China posted its second consecutive quarter of year-over-year double-digit growth on both a reported and local currency basis, up 11% and 17%, respectively. We are continuing to see positive momentum in several of our metrics, including active sales representatives, which was up 16% year-over-year. Asia Pacific was up 4% year-over-year on a reported basis and up 7% on a local currency basis. EMEA continues to outperform in the region, with net sales up 14% on a reported basis and 15% in local currency. The market experienced double-digit year-over-year increases in both active preferred customers and active distributors. EMEA net sales were up 4%, with local currency net sales up 7%. The year-over-year results were generally mixed across the markets in the region. In Latin America, net sales were up 4% on a reported basis and up 2% on a constant currency basis. This is the fifth consecutive quarter the region has reported a year-over-year increase in net sales. For the current quarter, year-over-year favorable FX impact was primarily due to the Mexican peso. Mexico's net sales were up 10% year-over-year on a reported basis, while relatively flat on a local currency basis on slightly lower volumes. During the first quarter, we continued to experience importation delays in Mexico as a result of the government's delay in timely approval importation permits, which stems for the importation hold placed on food supplements entering Mexico late last year, and this was not unique to Herbalife. However, our distributors are resilient. They consistently find new ways to overcome challenges which we believe contributed to the minimal decline in volumes year-over-year given the significant headwinds they faced exiting 2023. The year-over-year volume decline in Mexico was more than offset by 2 price increases implemented in the market following the first quarter of 2023. In North America, the decline in reported net sales were primarily driven by the U.S. market's 11% year-over-year decline. As Stephan noted in his remarks, several initiatives have been launched during the first quarter, which we believe are beginning to take root. We are encouraged to see the uptick in new distributors in the U.S. This is a positive leading indicator, which we are closely monitoring. Moving to the adjusted EBITDA bridge on Slide 11. We see the drivers of our 7% year-over-year increase in adjusted EBITDA. Q1 adjusted EBITDA was $138 million, with margin at 10.9%. As I previously mentioned, price increases, which were based mostly on CPI, exceeded higher input costs. The year-over-year increase in bonus is primarily due to the increased employee bonus accruals in the current period versus 2023, which were accrued at a significantly reduced achievement level. We expect this to continue for the remainder of 2024. Technology costs were up approximately $5 million year-over-year due to the increased SaaS hosting fees as we strategically pivoted to more SaaS-based arrangements in 2023. As I previously mentioned, the nonrepeat of the China government grant income recognized in the first quarter of last year, drove an approximate $9 million of unfavorable impact on adjusted EBITDA. The other changes include $7.5 million of favorable impact due to lower inventory write-downs in the first quarter of 2024 versus the same period last year due to significant efforts at the beginning of 2023 to rightsize our inventory levels. The remainder of other primarily relates to additional net SG&A savings mostly from the cost-reduction initiatives put in place and led by a dedicated task force. Moving to Slide 12, I'll provide an update on our capital structure. During the quarter, we lowered our overall debt by approximately $155 million, and we reduced our total leverage ratio from 3.9x at year-end to 3.6x at the end of Q1. Cash at the end of March was just under $400 million. As we took additional steps during the quarter to further leverage our in-house bank and better optimize our cash. Following the quarter, we completed a $1.6 billion senior secured refinancing, which included $800 million of senior secured notes due in April 2029, a $400 million 5-year term loan B facility and a $400 million full year revolving credit facility. Proceeds from the 2029 senior notes and the new term loan B, we used to repay all amounts outstanding under the 2018 credit facility, which included approximately [ $983 million ]. We also redeemed $300 million of the $600 million outstanding on the 2025 senior notes. In addition, last week, we separately repurchased an additional $38 million of the 2025 senior notes. The net result of the transactions is that we have pushed a vast majority of our debt maturities out to 2029. The only sizable maturity we face prior to 2028 is the $262 million outstanding on the 2025 notes, which we expect to pay off with cash generated from operations. Regarding interest expense, based on the approximately 240 basis points increase in the weighted average interest rate of our new debt structure and assuming the debt balance as of April 26, as noted on the slide, we are expecting full year net interest expense to be approximately $50 million to $60 million higher than 2023. And we remain committed to reducing our leverage ratio to 3x by the end of next year. Moving to Slide 13. We will review our outlook for the remainder of the year. First and foremost, we expect to continue to issue guidance every quarter going forward. For the second quarter, we expect net sales to be in the range of flat to a 3% increase year-over-year. We expect adjusted EBITDA to be in the range of $140 million to $160 million. A small decline from Q2 last year, which is primarily due to higher tech costs and higher employee costs as savings from the new restructuring program mostly in the back half of the year, as the majority of the actions are occurring during the second quarter. Looking at our planned capital expenditures for the second quarter, we expect it to be in the range of $30 million to $40 million. in line with Q2 of last year and Q1 of this year. Based on our results for the first quarter, and outlook for the remainder of the year, we are reaffirming our full-year 2024 net sales guidance of flat to a 5% increase year-over-year, and we are raising our expectations for full year adjusted EBITDA and to a range of $550 million to $590 million, and we are reducing our capital expenditure expectations to a range of $120 million to $150 million. The reduction in narrowing of our CapEx range is based on a thorough review of our technology and manufacturing plan. We have reprioritized development and implementation of certain applications related to Herbalife One and eliminated or postponed certain capital projects related to our manufacturing facilities. Capitalized SaaS implementation costs are expected to be in the range of $20 million to $25 million for the full year 2024. with approximately $5 million capitalized in the first quarter of 2024. A couple of last comments before we open up the call for questions. First, I'd like to provide an early but high-level outlook into our 2025 adjusted EBITDA margin improvement. Inherent in our 2024 full-year guidance today is that adjusted EBITDA margin that is not dissimilar from 2023. However, with our cost savings plans and modest growth expectations, we expect 2025 adjusted EBITDA margin to be a minimum of 100 basis points better than 2024. We get there with the full year impact of the reorganizational savings as well as an additional $35 million in savings that we have already identified, including incremental reduced tech spend. And of course, we're not stopping there. We are continuing to focus on driving costs out of the business and enhancing our margins, and we will provide more updates in the future. Second, as I previously said, we expect to repay the $262 million in bonds due in 2025 from cash flow generated by the business, much of which we expect to be generated this year. For my earlier comments regarding our 2024 cash flow expectations and our CapEx guidance provided today, you can calculate that we expect to generate nearly 2/3 of the free cash needed for this 2025 maturity in 2024. With the bond pay off in 2025, the minimum 100 basis point improvement in adjusted EBITDA margins in 2025 previously mentioned plus the add-backs for the credit agreement EBITDA for things such as share-based compensation, we now have line of sight to how we can achieve our 3x leverage ratio by the end of next year. This is an exciting time for Herbalife, and I could not be more proud of our team. I hope you walk away from today's call with the following. As Stephan described, our initiatives are driving increased distributor engagement. We can see a sales growth trajectory. We have additional opportunities to take costs out of the business. The cash generated from the business will be used to pay down debt. And one last key point. As Michael said earlier on the call, we are unique from every other direct selling company, and we will continue to capitalize on those assets as we move down our path to be the world's premier health and wellness company, community, and platform. Thank you. This concludes our opening remarks. Operator, please open the call for questions.